全文获取类型
收费全文 | 216373篇 |
免费 | 17321篇 |
国内免费 | 6960篇 |
专业分类
耳鼻咽喉 | 1252篇 |
儿科学 | 7629篇 |
妇产科学 | 1547篇 |
基础医学 | 19229篇 |
口腔科学 | 3603篇 |
临床医学 | 22875篇 |
内科学 | 54824篇 |
皮肤病学 | 2716篇 |
神经病学 | 25940篇 |
特种医学 | 6221篇 |
外国民族医学 | 4篇 |
外科学 | 16504篇 |
综合类 | 29876篇 |
现状与发展 | 31篇 |
一般理论 | 9篇 |
预防医学 | 17275篇 |
眼科学 | 2337篇 |
药学 | 15011篇 |
184篇 | |
中国医学 | 9927篇 |
肿瘤学 | 3660篇 |
出版年
2024年 | 395篇 |
2023年 | 4338篇 |
2022年 | 5843篇 |
2021年 | 11466篇 |
2020年 | 10926篇 |
2019年 | 8305篇 |
2018年 | 8227篇 |
2017年 | 8167篇 |
2016年 | 8492篇 |
2015年 | 8206篇 |
2014年 | 15559篇 |
2013年 | 17010篇 |
2012年 | 12726篇 |
2011年 | 13762篇 |
2010年 | 10828篇 |
2009年 | 10414篇 |
2008年 | 10429篇 |
2007年 | 10088篇 |
2006年 | 8985篇 |
2005年 | 7414篇 |
2004年 | 6306篇 |
2003年 | 5423篇 |
2002年 | 4568篇 |
2001年 | 3950篇 |
2000年 | 3294篇 |
1999年 | 2820篇 |
1998年 | 2702篇 |
1997年 | 2381篇 |
1996年 | 1861篇 |
1995年 | 1928篇 |
1994年 | 1773篇 |
1993年 | 1512篇 |
1992年 | 1452篇 |
1991年 | 1278篇 |
1990年 | 1011篇 |
1989年 | 858篇 |
1988年 | 804篇 |
1987年 | 732篇 |
1986年 | 633篇 |
1985年 | 736篇 |
1984年 | 617篇 |
1983年 | 379篇 |
1982年 | 446篇 |
1981年 | 374篇 |
1980年 | 282篇 |
1979年 | 247篇 |
1978年 | 184篇 |
1977年 | 164篇 |
1976年 | 135篇 |
1975年 | 49篇 |
排序方式: 共有10000条查询结果,搜索用时 281 毫秒
991.
目的:评价盐酸帕罗西汀治疗躯体疾病伴发焦虑的疗效。方法:对我院2002年1月-2003年.3月内外科躯体疾患伴发焦虑患者进行开放性平行对照研究,对照组用多虑平治疗,为期六周,采用HAMA、CGI量表评定临床效果,以TESS评定不良反应。结果:共65例(帕罗西汀31例,多虑平组34例),临床判断帕罗西汀与多虑平的显效率分别为66.7%和69.4%,无显著差异,治疗后一周,多虑平组HAMA减分率优于帕罗西汀组,治疗二周后无显著差异。副反应的发生率,帕罗西汀组为17.6%,远低于多虑平组的34.6%。结论:帕罗西汀是一种疗效好,安全性高的治疗躯体疾病伴发焦虑的首选药物。 相似文献
992.
Toshiyuki Matsui Sumio Tsuda Hiroaki Matake Keisuke Ikeda Tsuneyoshi Yao 《Digestive endoscopy》2004,16(Z1):S27-S30
Background: Gastrointestinal strictures are the most often and serious complication in Crohn's disease. Because of the frequent postoperative recurrence in Crohn's disease, endoscopic therapy of gastrointestinal stricture is one of the best therapeutic options. Method: The present study sets out the results from a prospective study of endoscopic dilation therapy on 48 Crohn's disease patients with severe gastrointestinal stenoses. All patients who could not undergo endoscopic balloon dilation therapy (EBD) were operated on. Results: Long‐term success was attained in 32 of the 48 patients; cumulative avoidance of surgery after EBD was 86% at one year and 71% at three. Second, the most hazardous factor was recurrent inflammation causing restenosis. Patients who had strictures with oral luminal dilatation and patients with frequent recurrence had a tendency to be operated on. As a complication, perforation occurred in two cases (3.3%). Conclusions: EBD therapy for Crohn's stricture in the gastrointestinal tract is recommended before surgical intervention. 相似文献
993.
目的应用间期荧光原位杂交技术(I-FISH)检测初诊急性白血病患者中核心结合因子(CBF)受累的染色体异常情况并对治疗后患者的微小残留病(MRD)进行监测,同时对I-FISH与常规染色体G显带的灵敏度进行比较。方法在骨髓形态学初筛的基础上,应用常规染色体G显带技术对15例急性髓系白血病(AML)进行核型分析,应用I-FISH对患者可能受累的CBF相关靶基因进行检测,其中7例患者治疗后进行了MRD监测。结果(1)正常对照组中,CYTOCELL公司提供的3种探针(AML1/ETO易位探针、MYH11基因断裂点双色探针和ETV6/AML1易位探针)的正常分界值分别为4.13%、1.95%和2.12%。(2)常规染色体G显带分析,15例患者中有6例伴有潜在累及CBF基因的染色体异常,其中8例AML-M2中5例伴t(8;21),2例AML-M4EO中1例伴inv(16),5例儿童B系急性淋巴细胞白血病(B-ALL)未检出相应的异常。I-FISH检测15例患者发现有12例累及CBF基因,其中8例AML-M2患者均为AML1/ETO融合基因(+),2例AML-M4EO病人CBFβ/MYH11融合基因均为(+),5例儿童B-ALL中2例ETV6/AML融合基因(+)。(3)3例AML-M2患者中2例MRD阳性;2例M4E0患者治疗后MRD监测结果均阴性;2例B-ALL患者1例阴性,1例阳性。结论I-FISH较常规染色体G显带技术能够更灵敏地检测出累及CBF的急性白血病,在初诊时联合应用这两种 相似文献
994.
非T细胞去除HLA单倍体匹配造血干细胞移植治疗白血病 总被引:4,自引:1,他引:3
目的:探讨相关HLA单倍体匹配造血千细胞移植治疗白血病的疗效及移植相关并发症。方法:4例白血病患者接受单倍体相合未去T细胞造血干细胞移植,3例为HLA-A、B、DR3个位点不合亲缘骨髓移植,1例为HLA-DR位点不合外周血造血干细胞移植,3例移植时处于完全缓解(CR)期,1例处于慢性粒细胞白细病(CML)急变期,预处理采用阿糖胞苷 环磷酰胺(CTX) 全身照射(TBI),Graft versus host disease(GVHD)预防联合使用环孢菌素A(CsA)、甲氨喋呤(MTX)、兔抗人胸腺细胞球蛋白(ATG)、抗CD25单抗、霉酚酸酯(MMF)。结果:4例均获得造血重建,植入直接证据检测证实完全供者造血,3例无aGVHD,1例发生Ⅱ度肠道aGVHD,1例移植后3个月复发,2例在行供者淋巴细胞输注治疗后均并发了Ⅲ度肠道和Ⅱ度肝脏aGVHD.免疫重建延迟。至今,3例存活( 70天- 19个月),均为持续完全缓解(CCR),1例 11个月因感染死亡。讨论:未去T细胞单倍体相合HSCT造血重建稳定,移植相关并发症较少,重症GVHD发生率可能低。 相似文献
995.
目的研究脑深部电刺激术(DBS)电极移位的原因及预防措施.方法研究113例帕金森病DBS术中及术后程控时的深部电极与预置靶点的差异.结果发生电极移位5例,其中术中发生2例;3例术中刺激效果满意,电极未发生移位,但术后4周程控时达不到满意效果,复查头颅MRI示脑深部电极移位,2例比原定位置深4 mm,1例比原定位置深6 mm.结论植入的刺激电极在颅内移位是影响DBS治疗效果的重要因素,可造成某些病人术中刺激效果好,但一段时间后疗效差的现象,应积极预防. 相似文献
996.
F. M. Ulivieri L. P. Piodi G. Marotta D. Marchelli C. Commadini L. Parravicini C. Verdoia P. Gerundini 《Journal of orthopaedics and traumatology》2006,7(4):192-194
Osteoprotegerin (OPG) is a protein that inhibits of osteoclastogenesis. The aim this study was to evaluate the response of
serum OPG levels to neridronate treatment in patients with Paget's disease of bone resistant to previous therapy. Nine patients
(4 men) affected by active Paget’s disease of bone (6 polyostotic, 3 monostotic) not responsive to clodronate were studied.
Serum OPG, osteocalcin, total and bone isoenzyme of alkaline phosphatase (AP and BAP, respectively), and urinary deoxypyridinoline
(DPD) were measured before and 5 months after neridronate treatment (100 mg/day, i.v. for two days). A scintigraphic activity
index (SAI) was also calculated before treatment. Mean baseline OPG levels were within normal values and were not significantly
different 5 months after neridronate treatment. In contrast, there were significant reductions in AP (41.9%, p<0.02) and BAP (38.8%, p<0.04). Serum OPG levels correlated with DPD (r=0.925) and SAI (r=0.689). Although OPG is an important regulator of bone metabolism,
in our series of already treated patients it was not a sensitive marker for diagnosing Paget's disease and for monitoring
the response to pharmacological treatment, whereas AP and BAP confirmed their clinical usefulness. This preliminary study
requires confirmation by a study with a larger population. 相似文献
997.
998.
Juan Carlos Gómez-Esteban Juan Jose Zarranz Elena Lezcano Fernando Velasco Roberto Ciordia Idoia Rouco Jose Losada Iker Bilbao 《Movement disorders》2006,21(7):983-988
The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 +/- 8.2 years, and duration of disease was 7.4 +/- 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 +/- 19.75 and on the UPDRS III scale was 25.24 +/- 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy. 相似文献
999.
Martin Krause Wolfgang Fogel Volker Tronnier Sabine Pohle Konstanze H?rtnagel Ute Thyen Jens Volkmann 《Movement disorders》2006,21(12):2255-2257
Pantothenate kinase-associated neurodegeneration (PKAN) is a rare autosomal recessive disorder with onset in childhood and rapid progression. There is no causative and insufficient symptomatic drug therapy. Deep brain stimulation (DBS) of the internal pallidum (GPi) has been reported to improve motor function. Most case reports, however, are limited to short observational periods. The impact of DBS on the progression and life expectancy in PKAN is unknown. We present a 5-year outcome and video documentation of bilateral GPi-DBS of an adolescent patient suffering from genetically defined PKAN. 相似文献
1000.
Calciphylaxis – a topical overview 总被引:3,自引:0,他引:3
G Arseculeratne† AT Evans‡ SM Morley† 《Journal of the European Academy of Dermatology and Venereology》2006,20(5):493-502
'Calciphylaxis', a calcification syndrome associated with ischaemic cutaneous necrosis, is acquired naturally in humans in disease states. It is a life and limb-threatening complication, usually observed in patients with renal disease and secondary hyperparathyroidism, but known to occur in the absence of renal or parathyroid disease. The reported mortality rate, which ranges from 60-80%, relates to wound infection, sepsis and organ failure. It is a small-vessel vasculopathy, which is estimated to occur in about 4% of haemodialysis patients. Clinically, violaceous, reticulate areas of cutaneous necrosis and eschar may be evident, particularly in the extremities. In addition to the clinical picture, a raised calcium phosphorous product, an elevated parathyroid hormone level, radiographic evidence of vessel and soft-tissue calcification and the finding of mural calcification affecting small arteries and arterioles on histopathology help to confirm the diagnosis of this entity which generally has a poor prognosis. A high index of suspicion and an active multidisciplinary management approach, with rigorous attention to wound care and prevention of sepsis, are vital in the management of these patients. In this overview, we discuss the pathophysiology, clinical features and associations, risk factors, diagnosis and management issues relating to calciphylaxis. 相似文献